Letters to the Editor
31 July 2025
New papers
Self-administered intranasal etripamil: a breakthrough in PSVT first-line treatment
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
50
Views
15
Downloads
Authors
Dear Editor,
PSVT, AVRT, and AVNRT are types of arrhythmia resulting from disruptions in the heart's electrical activity, originating from the sinoatrial node and propagating via the atria to the AV node, causing sudden symptoms like palpitations and dyspnea...
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Ferguson JD, DiMarco JP. Contemporary management of paroxysmal supraventricular tachycardia. Circulation 2003;107:1096–9. DOI: https://doi.org/10.1161/01.CIR.0000059743.36226.E8
2. Chu GS, Gupta D. Update on etripamil nasal spray for the at-home treatment of acute paroxysmal supraventricular tachycardia. Heart Int 2021;15:2-6. DOI: https://doi.org/10.17925/HI.2021.15.1.2
3. Stambler BS, Plat F, Sager PT, et al. First randomized, multicenter, placebo-controlled study of self-administered intranasal etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (NODE-301). Circ Arrhythm Electrophysiol 2022;15: e010915. DOI: https://doi.org/10.1161/CIRCEP.122.010915
4. Camm AJ, Ip JE, Coutu B, et al. Quality of life measures with etripamil self-administration for acute episodes of paroxysmal supraventricular tachycardia in a medically unsupervised setting: patient-reported outcomes from NODE-303. Eur Heart J 2024;45:ehae666. DOI: https://doi.org/10.1093/eurheartj/ehae666.631
5. Queiroz I, Barbosa L, Defante MLR, et al. Abstract 4137870: Nasal etripamil spray efficacy for acute paroxysmal supraventricular tachycardia: a systematic review, meta-analysis and trial sequential analysis. Circulation 2024;150. DOI: https://doi.org/10.1161/circ.150.suppl_1.4137870
How to Cite
1.
Khalid M, Asif A, Rasheed S. Self-administered intranasal etripamil: a breakthrough in PSVT first-line treatment . Global Cardiol [Internet]. 2025 Jul. 31 [cited 2025 Aug. 5];. Available from: https://www.globalcardiology.info/site/article/view/79
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
